Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Medtronic
Baxter
Johnson and Johnson
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Doravirine - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for doravirine and what is the scope of freedom to operate?

Doravirine is the generic ingredient in two branded drugs marketed by Msd Merck Co and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Doravirine has sixty-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for doravirine
International Patents:63
US Patents:1
Tradenames:2
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 33
Clinical Trials: 14
Patent Applications: 14
Drug Prices: Drug price trends for doravirine
DailyMed Link:doravirine at DailyMed
Drug Prices for doravirine

See drug prices for doravirine

Recent Clinical Trials for doravirine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institut d'Investigació Biomèdica de BellvitgePhase 3
Institut d'Investigació Biomèdica de BellvitgePhase 2
Hospital Universitari de BellvitgePhase 3

See all doravirine clinical trials

Synonyms for doravirine
1338225-97-0
2KW
3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile
3-Chloro-5-({1-[(4-Methyl-5-Oxo-4,5-Dihydro-1h-1,2,4-Triazol-3-Yl)methyl]-2-Oxo-4-(Trifluoromethyl)-1,2-Dihydropyridin-3-Yl}oxy)benzonitrile
3-chloro-5-[[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-3-pyridyl]oxy]benzonitrile
3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile
4ncg
913P6LK81M
AKOS030528603
BCP02296
Benzonitrile, 3-chloro-5-((1-((4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl)-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl)oxy)-
CHEMBL2364608
CS-5924
D10624
DB12301
Doravirine (JAN/USAN/INN)
Doravirine (MK-1439)
Doravirine [USAN:INN]
Doravirine; MK-1439
DTXSID30158386
EX-A1968
HY-16767
MFCD22417167
MK 1439
MK-1439
MK-1439(Doravirine)
MK1439
Pifeltro (TN)
S900006160
SB17104
SCHEMBL2509885
UNII-913P6LK81M
ZIAOVIPSKUPPQW-UHFFFAOYSA-N
ZINC72317283

US Patents and Regulatory Information for doravirine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co DELSTRIGO doravirine; lamivudine; tenofovir disoproxil fumarate TABLET;ORAL 210807-001 Aug 30, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Msd Merck Co PIFELTRO doravirine TABLET;ORAL 210806-001 Aug 30, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Msd Merck Co DELSTRIGO doravirine; lamivudine; tenofovir disoproxil fumarate TABLET;ORAL 210807-001 Aug 30, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Msd Merck Co DELSTRIGO doravirine; lamivudine; tenofovir disoproxil fumarate TABLET;ORAL 210807-001 Aug 30, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Msd Merck Co PIFELTRO doravirine TABLET;ORAL 210806-001 Aug 30, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for doravirine

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2924034 CA 2019 00024 Denmark   Start Trial PRODUCT NAME: DORAVIRINE, LAMIVUDINE AND DISOPROXIL; REG. NO/DATE: EU/1/18/1333 20181126
2924034 2019C/005 Belgium   Start Trial PRODUCT NAME: DORAVIRINE,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT IN COMBINATIE MET LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAARZOUT, IN COMBINATIE MET TENOFOVIR OF EEN ESTER DAARVAN, IN HET BIJZONDER EEN DISOPROXIL ESTER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER EEN FUMARAAT ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1333/001-002 20181126
2552902 2019C/004 Belgium   Start Trial PRODUCT NAME: DORAVIRINE,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1333/001-002 20181126
2552902 2019/020 Ireland   Start Trial PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1332/001, EU/1/18/1332/002, EU/1/18/1333/001, EU/1/18/1333/002, 20181122
2924034 122019000042 Germany   Start Trial PRODUCT NAME: DORAVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DAVON IN KOMBINATION MIT LAMIVUDIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DAVON IN KOMBINATION MIT TENOFOVIR ODER EINEM ESTER DAVON, EINSCHLIESSLICH EINEM DISOPROXILESTER, ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DAVON, EINSCHLIESSLICH EINEM FUMARATSALZ; REGISTRATION NO/DATE: EU/1/18/1333 20181122
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
McKinsey
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.